JO3624B1 - تركيبات إنسولين سريعة المفعول - Google Patents

تركيبات إنسولين سريعة المفعول

Info

Publication number
JO3624B1
JO3624B1 JOP/2015/0079A JOP20150079A JO3624B1 JO 3624 B1 JO3624 B1 JO 3624B1 JO P20150079 A JOP20150079 A JO P20150079A JO 3624 B1 JO3624 B1 JO 3624B1
Authority
JO
Jordan
Prior art keywords
acting insulin
fast acting
insulin formulations
insulin
formulations
Prior art date
Application number
JOP/2015/0079A
Other languages
English (en)
Inventor
Edward CHRISTE Michael
Andrew HARDY Thomas
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53189204&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JO3624(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of JO3624B1 publication Critical patent/JO3624B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Dermatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

يتعلق الاختراع الحالي بتركيبة إنسولين بشري أو نظير إنسولين تتضمن تربروستينيل ولها مفعول دوأئي أسرع من الصيغ التجارية لمنتجات نظير الإنسولين الحالية.
JOP/2015/0079A 2014-05-08 2015-04-21 تركيبات إنسولين سريعة المفعول JO3624B1 (ar)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201461990402P 2014-05-08 2014-05-08

Publications (1)

Publication Number Publication Date
JO3624B1 true JO3624B1 (ar) 2020-08-27

Family

ID=53189204

Family Applications (1)

Application Number Title Priority Date Filing Date
JOP/2015/0079A JO3624B1 (ar) 2014-05-08 2015-04-21 تركيبات إنسولين سريعة المفعول

Country Status (36)

Country Link
US (2) US9439952B2 (ar)
EP (3) EP3943155A1 (ar)
JP (1) JP6050902B2 (ar)
KR (1) KR101858890B1 (ar)
CN (1) CN106456717B (ar)
AP (1) AP2016009525A0 (ar)
AR (1) AR100155A1 (ar)
AU (1) AU2015256355B2 (ar)
BR (1) BR112016024357B1 (ar)
CA (1) CA2945188C (ar)
CL (1) CL2016002772A1 (ar)
CY (2) CY1121669T1 (ar)
DK (2) DK3140008T3 (ar)
EA (1) EA031134B1 (ar)
ES (2) ES2733639T3 (ar)
HR (2) HRP20190777T1 (ar)
HU (2) HUE044370T2 (ar)
IL (1) IL248350B (ar)
JO (1) JO3624B1 (ar)
LT (2) LT3140008T (ar)
MA (1) MA39441A1 (ar)
ME (1) ME03384B (ar)
MX (1) MX367521B (ar)
NZ (1) NZ724919A (ar)
PE (1) PE20161408A1 (ar)
PH (1) PH12016502195B1 (ar)
PL (2) PL3536380T3 (ar)
PT (2) PT3140008T (ar)
RS (2) RS58726B1 (ar)
SG (1) SG11201608424WA (ar)
SI (2) SI3140008T1 (ar)
TN (1) TN2016000443A1 (ar)
TR (1) TR201906843T4 (ar)
TW (1) TWI685348B (ar)
UA (1) UA124919C2 (ar)
WO (1) WO2015171484A1 (ar)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2010009850A (es) 2008-03-18 2010-09-30 Novo Nordisk As Analogos de insulina acilados y etabilizados contra proteasas.
KR20150082640A (ko) 2012-11-13 2015-07-15 아도시아 치환된 음이온성 화합물을 포함하는 속효성 인슐린 제형
US9505737B2 (en) 2013-01-11 2016-11-29 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
US9371264B2 (en) 2013-01-11 2016-06-21 Corsair Pharma, Inc. Treprostinil derivative compounds and methods of using same
ES2972423T3 (es) * 2015-07-28 2024-06-12 Lilly Co Eli Preparado farmacéutico para mejorar la absorción y la acción hipoglucemiante postprandial de la insulina
JO3749B1 (ar) * 2015-08-27 2021-01-31 Lilly Co Eli تركيبات إنسولين سريعة المفعول
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
GB201607918D0 (en) 2016-05-06 2016-06-22 Arecor Ltd Novel formulations
EP3515430A1 (en) 2016-09-26 2019-07-31 United Therapeutics Corporation Treprostinil prodrugs
AU2017334290B2 (en) 2016-09-29 2023-04-20 Arecor Limited Novel formulations
MA49116A (fr) 2016-12-16 2020-03-25 Novo Nordisk As Compositions pharmaceutiques contenant de l'insuline
GB201707189D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707188D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
GB201707187D0 (en) 2017-05-05 2017-06-21 Arecor Ltd Novel formulations
WO2018222787A1 (en) * 2017-06-01 2018-12-06 Eli Lilly And Company Rapid-acting insulin compositions
WO2019193349A1 (en) 2018-04-04 2019-10-10 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
IL277721B2 (en) 2018-04-04 2024-03-01 Arecor Ltd Medical infusion pump system for the delivery of an insulin compound
US20210113763A1 (en) 2018-04-04 2021-04-22 Arecor Limited Medical infusion pump system for the delivery of an insulin compound
FR3083985A1 (fr) 2018-07-23 2020-01-24 Adocia Dispositif pour injecter une solution d'insuline(s)
WO2019243627A1 (fr) 2018-06-23 2019-12-26 Adocia Dispositif pour injecter une solution d'insuline(s)
US12102610B2 (en) 2018-09-18 2024-10-01 Eli Lilly And Company Treprostinil salt
US10799564B1 (en) 2019-05-06 2020-10-13 Baxter International Inc. Insulin premix formulation and product, methods of preparing same, and methods of using same
CN114096269B (zh) 2019-07-12 2024-06-11 诺和诺德股份有限公司 高浓度胰岛素制剂
JP2022546314A (ja) 2019-08-23 2022-11-04 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグ
GB202004814D0 (en) 2020-04-01 2020-05-13 Arecor Ltd Novel formulations
US11826327B2 (en) 2020-04-17 2023-11-28 United Therapeutics Corporation Treatment for interstitial lung disease
KR20250057075A (ko) 2020-06-09 2025-04-28 유나이티드 쎄러퓨틱스 코포레이션 트레프로스티닐의 푸마릴 디케토피페리딘 프로드러그
TW202214292A (zh) * 2020-06-30 2022-04-16 大陸商江蘇恆瑞醫藥股份有限公司 速效胰島素組成物及其醫藥用途
JP7826317B2 (ja) 2020-12-14 2026-03-09 ユナイテッド セラピューティクス コーポレイション トレプロスチニルプロドラッグで疾患を治療する方法
EP4301372A1 (en) 2021-03-03 2024-01-10 United Therapeutics Corporation A dry powder composition of trestinil and its prodrug thereof and further comprising comprising (e)-3,6-bis[4-(n-carbonyl-2-propenyl)amidobutyl]-2,5-diketopiperazine (fdkp)
KR20250002687A (ko) * 2022-04-29 2025-01-07 자오커 파마슈티컬 (광저우) 컴퍼니., 리미티드 트레프로스티닐 소프트 미스트 흡입제

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2740953A1 (de) 1977-09-12 1979-03-22 Thera Ges Fuer Patente Verwendung von prostaglandinen zur senkung des blutzuckerspiegels
JPH10251146A (ja) * 1997-03-11 1998-09-22 Toray Ind Inc 糖尿病性神経障害の治療方法
WO2003020201A2 (en) * 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
ATE496064T1 (de) * 2002-05-07 2011-02-15 Novo Nordisk As Lösliche formulierungen, die monomeres insulin und acyliertes insulin enthalten
CN101287457B (zh) * 2004-04-12 2011-11-16 联合治疗公司 Treprostinil用于治疗神经性糖尿病的足部溃疡的用途
EP2190433A2 (en) * 2007-08-22 2010-06-02 Gilead Colorado, Inc. Therapy for complications of diabetes
US9387033B2 (en) 2008-08-28 2016-07-12 Roche Diabetes Care, Inc. Device and method for enhanced subcutaneous insulin absorption
EP2330893A4 (en) * 2008-09-25 2013-01-09 Aradigm Corp DEEP PULMONARY ADMINISTRATION OF TREPROSTINIL
KR101775000B1 (ko) 2009-06-26 2017-09-04 노보 노르디스크 에이/에스 인슐린, 니코틴아미드 및 아미노산을 포함하는 제제
BR112012011237A2 (pt) * 2009-11-13 2019-09-24 Univ Tokyo agente terapêutico e profilático para diabetes
CN103328006A (zh) 2010-12-14 2013-09-25 诺沃—诺迪斯克有限公司 包含胰岛素、烟酰胺和氨基酸的制剂
JP6092867B2 (ja) * 2011-08-12 2017-03-08 アセンディス ファーマ エー／エス 担体連結しているトレプロスチニルプロドラッグ
US9381247B2 (en) * 2012-04-16 2016-07-05 Biodel Inc. Magnesium compositions for modulating the pharmacokinetics and pharmacodynamics of insulin and insulin analogs, and injection site pain
US20150065423A1 (en) 2013-08-30 2015-03-05 Perosphere, Inc. Rapid acting injectable formulations
WO2015120457A1 (en) 2014-02-10 2015-08-13 Biodel Inc. Stabilized ultra-rapid-acting insulin formulations

Also Published As

Publication number Publication date
PT3536380T (pt) 2021-09-02
EA031134B1 (ru) 2018-11-30
US9439952B2 (en) 2016-09-13
IL248350B (en) 2020-03-31
EA201691911A1 (ru) 2017-02-28
UA124919C2 (uk) 2021-12-15
AU2015256355B2 (en) 2017-09-14
DK3536380T3 (da) 2021-08-02
KR20160133567A (ko) 2016-11-22
PH12016502195A1 (en) 2017-02-06
CA2945188C (en) 2018-12-11
ME03384B (me) 2020-01-20
HUE055742T2 (hu) 2021-12-28
HRP20211415T1 (hr) 2021-12-10
TR201906843T4 (tr) 2019-05-21
PE20161408A1 (es) 2016-12-28
EP3536380B8 (en) 2021-09-22
PT3140008T (pt) 2019-06-25
TN2016000443A1 (en) 2018-04-04
CL2016002772A1 (es) 2017-06-09
SI3536380T1 (sl) 2021-09-30
RS62291B1 (sr) 2021-09-30
PH12016502195B1 (en) 2017-02-06
MX2016014643A (es) 2017-03-06
EP3140008A1 (en) 2017-03-15
LT3536380T (lt) 2021-08-10
CY1121669T1 (el) 2020-07-31
BR112016024357A2 (pt) 2017-10-10
US10172922B2 (en) 2019-01-08
SG11201608424WA (en) 2016-11-29
EP3536380A1 (en) 2019-09-11
AU2015256355A1 (en) 2016-10-27
AP2016009525A0 (en) 2016-10-31
AR100155A1 (es) 2016-09-14
CA2945188A1 (en) 2015-11-12
JP6050902B2 (ja) 2016-12-21
EP3943155A1 (en) 2022-01-26
DK3140008T3 (da) 2019-06-24
MA39441A1 (fr) 2017-06-30
PL3140008T3 (pl) 2019-09-30
MX367521B (es) 2019-08-26
KR101858890B1 (ko) 2018-05-16
PL3536380T3 (pl) 2021-12-27
CN106456717B (zh) 2020-01-17
ES2891983T3 (es) 2022-02-01
HRP20190777T1 (hr) 2019-08-23
JP2016523807A (ja) 2016-08-12
HUE044370T2 (hu) 2019-10-28
SI3140008T1 (sl) 2019-06-28
ES2733639T3 (es) 2019-12-02
CN106456717A (zh) 2017-02-22
US20160367640A1 (en) 2016-12-22
EP3140008B1 (en) 2019-04-17
US20160129087A1 (en) 2016-05-12
EP3536380B1 (en) 2021-07-07
IL248350A0 (en) 2016-11-30
TWI685348B (zh) 2020-02-21
TW201625291A (zh) 2016-07-16
BR112016024357B1 (pt) 2022-08-23
WO2015171484A1 (en) 2015-11-12
NZ724919A (en) 2018-01-26
LT3140008T (lt) 2019-05-27
CY1124454T1 (el) 2022-07-22
RS58726B1 (sr) 2019-06-28

Similar Documents

Publication Publication Date Title
JO3624B1 (ar) تركيبات إنسولين سريعة المفعول
MX2016008978A (es) Formulaciones farmaceuticas de analogos de insulina y/o derivados de insulina estabilizadas y que estan libres de glicerol.
MX2016008979A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
IL249061B (en) Combination, composition, and method of administering the combination or composition to animals
MX2020002693A (es) Formulaciones farmaceuticas estabilizadas de analogos de insulina y/o derivados de insulina.
MX2017001279A (es) Usos y composiciones de la flagelina.
DOP2018000059A (es) Composiciones de insulina de rápida acción
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
PH12017500836A1 (en) Transdermal formulations
IL253619A0 (en) Encapsulation of high potency active agents
CL2019002729A1 (es) Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico.
BR112016020181A2 (pt) Composições de ácido lipoico éster colina e métodos de uso.
MX2018007390A (es) Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo.
EP3197498C0 (en) COMPOSITIONS CONTAINING INACTIVATED BUT THERAPEUTICALLY ACTIVE BIOPHARMACEUTICALS, STABLE AT ROOM TEMPERATURE AND ASSOCIATED FORMULATION METHODS
MX377774B (es) Formulaciones de proteinas.
EP3110891A4 (en) Low-voc compositions and methods of making and using the same
MX379126B (es) Formulación de factor viii.
MX2016005545A (es) Analogo de la relaxina humana, composicion farmaceutica del mismo y aplicacion farmaceutica del mismo.
MX373197B (es) Formulaciones estables de undecanoato de testosterona.
MY167350A (en) Fat-and-oil composition and chocolate
PH12017501979A1 (en) Pharmaceutical compound
PH12018501166B1 (en) Concentrated gibberellin solution formulations
MX383460B (es) Derivados peptidicos novedosos y sus usos.
IN2015CH01454A (ar)
TH1501004860A (th) อินซูลินอะนาล็อก (insulin analog) ใหม่ และการใช้ของมัน